Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
2016
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance.
All three scenarios represent a cost-effective use of resources and would avert 800,000–1 million DALYs per year in India relative to the current scenario. However, especially in poor regions and populations, scenario 1 does not decrease the OOP expenditure or provide financial risk protection if care-seeking costs were included. The OOP expenditure averted increases from scenarios 1 through 3, and the money-metric value of insurance follows a similar trend between scenarios and typically decreases with wealth. In the first 10 years of scenarios 2 and 3, households avert on average over US$80 million per year in medical expenditure.
Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
Source:
Megiddo I, Colson A, Chisholm D et al. Health and Economic Benefits of Public Financing of Epilepsy Treatment in India: An Agent-Based Simulation Model. Epilepsia 2016; 57 (3): 464-474. https://doi.org/10.1111/epi.13294